XML 73 R56.htm IDEA: XBRL DOCUMENT
v3.25.4

License Agreements & Ducentis Acquisition - Ducentis Acquisition (Details) - USD ($) |  | 12 Months Ended
--- | --- | ---
Sep. 07, 2022 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023
Asset Acquisition [Line Items] |  |  |  |
Research and development |  | $ 77,051,000 | $ 76,420,000 | $ 110,575,000
Ducentis Biotherapeutics LTD Equity Interests |  |  |  |
Asset Acquisition [Line Items] |  |  |  |
Equity interest issued or issuable, number of shares (in shares) | 610,258 |  |  |
Consideration transferred | $ 15,900,000 |  |  |
Future payable milestone payment | 400,000,000 |  |  |
Contingent consideration to be transferred | $ 10,000,000.0 |  |  |
Contingent consideration, duration due within | 1 year |  |  |
Annual net sales | $ 1,500,000,000 |  |  |
Research and development | 29,600,000 |  |  |
License agreement, cash payment |  | $ 0 | $ 0 | $ 0
Ducentis Biotherapeutics LTD Equity Interests | Common Stock |  |  |  |
Asset Acquisition [Line Items] |  |  |  |
Consideration transferred, equity interest issued and issuable | $ 12,500,000 |  |  |

X
- Definition Asset Acquisition, Annual Net Sales of Acquiree Threshold + References No definition available. + Details
Name: | arqt_AssetAcquisitionAnnualNetSalesOfAcquireeThreshold
Namespace Prefix: | arqt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Consideration Transferred, Gross + References No definition available. + Details
Name: | arqt_AssetAcquisitionConsiderationTransferredGross
Namespace Prefix: | arqt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Contingent Consideration To Be Transferred Upon The Achievement Of Regulatory Milestones + References No definition available. + Details
Name: | arqt_AssetAcquisitionContingentConsiderationToBeTransferredUponTheAchievementOfRegulatoryMilestones
Namespace Prefix: | arqt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Contingent Payments, Duration Due Within First Enrollment + References No definition available. + Details
Name: | arqt_AssetAcquisitionContingentPaymentsDurationDueWithinFirstEnrollment
Namespace Prefix: | arqt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares + References No definition available. + Details
Name: | arqt_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares
Namespace Prefix: | arqt_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Payments, Milestones, Or Royalties, Future Payable Amount + References No definition available. + Details
Name: | arqt_AssetAcquisitionPaymentsMilestonesOrRoyaltiesFuturePayableAmount
Namespace Prefix: | arqt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=arqt_DucentisBiotherapeuticsLTDEquityInterestsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |